Breast cancer highlights from ESMO 2018
Breast cancer highlights from ESMO 2018
Editor’s Choice for October 2018
The IMpower-132 trial for non small cell lung cancer
ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD 1 refractory melanoma
Keynote lecture: Mutation signatures and targeting the DNA damage response
Dosing regiment in the combination of ipilimumab and nivolumab in stage III melanoma
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma
Modern melanoma treatment in the UK
Latest advances in treatment for ALK positive NSCLC
The case for biosimilars
Highlights in early non-metastatic NSCLC and thoracic tumours
Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC